- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Interventions
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Covid19
- Interventions
- COVID-19 vaccine
- Biological
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11,834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Covid-19, Subjects Vaccinated Against Covid-19
- Interventions
- Change in SARS-CoV-2 Antibody Levels
- Other
- Lead sponsor
- Dr. Sidney J. Stohs
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10,000 participants
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Southlake, Texas
- Conditions
- SARS-CoV-2
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,501 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- COVID-19
- Interventions
- Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
- Conditions
- Adverse Reaction to Vaccine, COVID19 Vaccine
- Interventions
- BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
- Biological
- Lead sponsor
- Masaryk University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Influenza, COVID-19
- Interventions
- Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 8,795 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 106
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
- Conditions
- COVID-19
- Interventions
- Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Interventions
- COVID-19 Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Interventions
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
- Interventions
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Biological
- Lead sponsor
- Sarang K. Yoon, DO, MOH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Covid19
- Interventions
- CVXGA1 low dose, CVXGA1 high dose
- Biological
- Lead sponsor
- CyanVac LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more
- Conditions
- COVID-19, Kidney Transplant
- Interventions
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- COVID-19
- Interventions
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SARS CoV 2 Infection, COVID-19
- Interventions
- Pfizer/BioNTech (BNT162b2), Moderna
- Biological
- Lead sponsor
- DHR Health Institute for Research and Development
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
- Conditions
- SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
- Interventions
- Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years and older
- Enrollment
- 746 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
- Biological · Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer
- Interventions
- COVID-19 Vaccination
- Biological
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Covid19
- Interventions
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 11 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 2 more
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Kidney Transplant Recipient
- Interventions
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Biological · Other
- Lead sponsor
- Mark Stegall
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection
- Interventions
- BNT162b2 (Tozinameran)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,277,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York